Total elimination of measles in Finland

被引:11
作者
Heinonen, OP
Paunio, M
Peltola, H
机构
[1] Hosp Children & Adolescents, FIN-00029 HUCH, Finland
[2] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Helsinki, Finland
关键词
elimination; eradication; measles; measles-mumps-rubella; MMR; vaccination;
D O I
10.3109/07853899808999395
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
On average, 15 000 cases of measles occurred annually in Finland before the initiation of a vaccination programme in 1975. Because of insufficient activity, the vaccination coverage failed to reach the required level of over 90%, and cases continued to occur. The policy was revolutionized in 1982 by Launching a project in which the Schwarz strain was substituted by an attenuated Enders-Edmonston strain given as a component of a trivalent live-virus measles-mumps-rubella vaccine (MMRII(R)). This vaccine is given twice, at the ages of 14-18 months and 6 years. The impact of the vaccinations has been monitored in several prospective studies. In addition to a very favourable safety profile, good immunogenicity and excellent clinical effectiveness have also been demonstrated. Since 1996 not a single case of measles has been found in Finland, although cases have been searched actively and serological confirmation has been required. Total interruption of virus circulation has brought a new problem: the possibility of vaccinees to acquire natural boosters is so rare that waning immunity has become a reality. As there is a continuous risk of measles originating from a foreign source, the only tool against an outbreak is to maintain a high vaccination coverage and to continue the two-dose schedule as a minimum policy.
引用
收藏
页码:131 / 133
页数:3
相关论文
共 20 条
[1]   AN EXPLOSIVE POINT-SOURCE MEASLES OUTBREAK IN A HIGHLY VACCINATED POPULATION - MODES OF TRANSMISSION AND RISK-FACTORS FOR DISEASE [J].
CHEN, RT ;
GOLDBAUM, GM ;
WASSILAK, SGF ;
MARKOWITZ, LE ;
ORENSTEIN, WA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1989, 129 (01) :173-182
[2]   PERSISTENCE OF ANTI-MUMPS VIRUS-ANTIBODIES AFTER A 2 DOSE MMR VACCINATION - A 9-YEAR FOLLOW-UP [J].
DAVIDKIN, I ;
VALLE, M ;
JULKUNEN, I .
VACCINE, 1995, 13 (16) :1617-1622
[3]   Measles elimination in the Americas - Evolving strategies [J].
deQuadros, CA ;
Olive, JM ;
Hersh, BS ;
Strassburg, MA ;
Henderson, DA ;
BrandlingBennett, D ;
Alleyne, GAO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (03) :224-229
[4]  
DITTMANN S, 1976, B WORLD HEALTH ORGAN, V53, P21
[5]  
FOEGE WH, 1971, SCI PUBLICATION PAN, V226, P207
[6]   SAFE IMMUNIZATION OF ALLERGIC CHILDREN AGAINST MEASLES, MUMPS, AND RUBELLA [J].
JUNTUNENBACKMAN, K ;
PELTOLA, H ;
BACKMAN, A ;
SALO, OP .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1987, 141 (10) :1103-1105
[7]   THE ROLE OF SECONDARY VACCINE FAILURES IN MEASLES OUTBREAKS [J].
MATHIAS, RG ;
MEEKISON, WG ;
ARCAND, TA ;
SCHECHTER, MT .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1989, 79 (04) :475-478
[8]   ACUTE THROMBOCYTOPENIC PURPURA FOLLOWING MEASLES, MUMPS AND RUBELLA VACCINATION - A REPORT ON 23 PATIENTS [J].
NIEMINEN, U ;
PELTOLA, H ;
SYRJALA, MT ;
MAKIPERNAA, A ;
KEKOMAKI, R .
ACTA PAEDIATRICA, 1993, 82 (03) :267-270
[9]  
PANUM PL, 1939, MED CLASSICS, V3, P829
[10]   INCREASE OF VACCINATION COVERAGE BY MASS-MEDIA AND INDIVIDUAL APPROACH - INTENSIFIED MEASLES, MUMPS, AND RUBELLA PREVENTION PROGRAM IN FINLAND [J].
PAUNIO, M ;
VIRTANEN, M ;
PELTOLA, H ;
CANTELL, K ;
PAUNIO, P ;
VALLE, M ;
KARANKO, V ;
HEINONEN, OP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1991, 133 (11) :1152-1160